Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Bintalib (London, United Kingdom), S. Abbas (London, United Kingdom), K. Warnatz (Freiburg, Germany), J. Hurst (and On Behalf Of The Eglildnet Consortium) (London, United Kingdom). Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD): an international research prioritisation. 4234

Member's Comments

No comment yet.

Related content which might interest you: The European research collaboration for Children's Interstitial Lung Disease (ChILDEU) ERS Clinical Research Collaboration Source: Eur Respir J, 52 (6) 1801855; 10.1183/13993003.01855-2018 Year: 2018 Value of community based Pulmonary Rehabilitation (PR) for patients with Interstitial Lung Disease (ILD): A retrospective review Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Translation and validation of the King's brief interstitial lung disease (K-BILD) questionnaire in French, Italian and Dutch Source: International Congress 2014 – ILDs 2 Year: 2014 Gender perspective in Interstitial Lung Diseases (ILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (5) 1900539; 10.1183/13993003.00539-2019 Year: 2019 Translation and preliminary validation of the KBILD QOL questionnaire to Spanish Source: International Congress 2014 – ILDs 6 Year: 2014 Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 Source: Eur Respir J, 53 (5) 1900164; 10.1183/13993003.00164-2019 Year: 2019 Cryptogenic organising pneumonia focusing on its prognostic determinants Source: International Congress 2014 – ILDs 4 Year: 2014 Hypersentivity pneumonitis in an Interstitial Lung Disease Unit, 5 years’ experience Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 GPs Meet Rare Lung Disorders Task Force factsheet: childhood interstitial lung disease Source: Breathe 2014; 10:173-175 Year: 2014 Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used Source: International Congress 2017 – Rare diseases Year: 2017 Health-related quality of life in idiopathic pulmonary fibrosis (IPF): First results based on the European IPF registry Source: International Congress 2014 – ILDs 1 Year: 2014 Collaborating with stakeholders to advance the National Patient Charter for Idiopathic Pulmonary Fibrosis in Ireland. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Unclassifiable Interstitial Lung Disease (ILD). Why? Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 What motivates primary healthcare practitioners to refer patients with Chronic Obstructive Pulmonary Disease (COPD) to Pulmonary Rehabilitation? A survey using the Theoretical Domains Framework. Source: Virtual Congress 2020 – Organising respiratory disease management in primary care Year: 2020 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 GPS and Rare Lung Diseases (RLDs): an ERS statement  for the development of RLD guidelines for general practice  Source: International Congress 2016 – ERS statements and technical standards Year: 2016 An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features Source: Eur Respir J 2015; 46: 976-987 Year: 2015